Oncotype DX testing for breast, colon, and prostate cancers for the indianapolis, indiana VA medical center for a base + 4 year order.

Active Awarded Last action

Contract number
36C25022F0243
Awardee
Awarding agency
Obligated
$61,449

Award facts

Contract value 56% obligated
  • $61,448.67 Current, with exercised options
  • $109,342.62 Potential, with all options
Completion date 96% complete
Current and potential, with all options
Contracting staff
NAICS code
621511 Medical Laboratories
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Redwood City, CA 94063, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Exercise an Option P00006 · Oncotype DX testing exercise OY 4 $23,164
Supplemental Agreement for work within scope P00005 · Oncotype DX testing decrease OY 1 & OY 2 -$54,079
Exercise an Option P00004 · Oncotype DX testing exercise OY 3 $23,164
Exercise an Option P00003 $23,164
Supplemental Agreement for work within scope P00002 · Oncotype DX testing decrease OY 1 -$32,221
Exercise an Option P00001 · Oncotype DX testing exercise option year $39,128
Original award $39,128

About this award

The Department of Veterans Affairs, Veterans Integrated Service Network 10, awarded a delivery order valued at $109,342.62 to Exact Sciences Corporation for Oncotype DX testing services at the Indianapolis, Indiana VA Medical Center. The contract, issued on January 15, 2022, with a completion date of January 14, 2027, encompasses a base period plus four-year option for genomic assay testing for breast, colon, and prostate cancers. This award was made without a set-aside designation under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule, reflecting Exact Sciences' competitive positioning as a specialized provider of cancer diagnostic testing to federal healthcare agencies.

Exact Sciences Laboratories, LLC, the division performing under this contract at its Redwood City, California facility, delivers advanced gene expression profiling and molecular diagnostic services that support the VA's oncology treatment protocols and personalized medicine initiatives. The company has established itself as a key federal contractor across multiple VA facilities and the Defense Health Agency through similar arrangements, including several blanket purchase agreements ranging up to $5 million for comparable oncology testing services. This delivery order represents one component of Exact Sciences' broader portfolio of cancer screening and diagnostic testing services provided to the VA and Department of Defense healthcare systems.

Quick answers

Who was awarded contract 36C25022F0243?

36C25022F0243 was awarded to Exact Sciences Corporation by Veterans Integrated Service Network 10 (Veterans Health Administration) on January 15, 2022.

How much is contract 36C25022F0243 worth?

The government has obligated $61,449 on 36C25022F0243. Its potential value, with all options, is $109,343.

Is contract 36C25022F0243 an order under another contract?

Yes. 36C25022F0243 is a delivery order under V797D70053, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).

Was contract 36C25022F0243 competed?

The extent of competition for 36C25022F0243 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award